These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Obesity and endocrine therapy: host factors and breast cancer outcome. Goodwin PJ Breast; 2013 Aug; 22 Suppl 2():S44-7. PubMed ID: 24074791 [TBL] [Abstract][Full Text] [Related]
8. The importance of nonpharmacogenetic factors in endocrine therapy. McCowan C; Thompson AM Pharmacogenomics; 2012 Apr; 13(6):721-8. PubMed ID: 22515614 [TBL] [Abstract][Full Text] [Related]
9. Aromatase inhibitors for the treatment of breast cancer: is tamoxifen of historical interest only? Van Poznak CH; Hayes DF J Natl Cancer Inst; 2006 Sep; 98(18):1261-3. PubMed ID: 16985239 [No Abstract] [Full Text] [Related]
10. Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy. Wheler J; Johnson M; Seidman A Semin Oncol; 2006 Dec; 33(6):672-80. PubMed ID: 17145347 [TBL] [Abstract][Full Text] [Related]
11. [Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer]. Tuxen MK; Nielsen DL; Lindberg H; Kamby C Ugeskr Laeger; 2007 Jan; 169(4):297-9. PubMed ID: 17274922 [TBL] [Abstract][Full Text] [Related]
12. Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer. Dent SF; Gaspo R; Kissner M; Pritchard KI Breast Cancer Res Treat; 2011 Apr; 126(2):295-310. PubMed ID: 21249443 [TBL] [Abstract][Full Text] [Related]
13. Sequential therapy with tamoxifen and aromatase inhibitors in early-stage postmenopausal breast cancer: a review of the evidence. Litsas G Oncol Nurs Forum; 2008 Jul; 35(4):714-21. PubMed ID: 18591176 [TBL] [Abstract][Full Text] [Related]
14. Aromatase inhibitors in breast cancer: an overview. Altundag K; Ibrahim NK Oncologist; 2006 Jun; 11(6):553-62. PubMed ID: 16794235 [TBL] [Abstract][Full Text] [Related]
15. Update on aromatase inhibitors in breast cancer. Gould RE; Garcia AA Curr Opin Obstet Gynecol; 2006 Feb; 18(1):41-6. PubMed ID: 16493259 [TBL] [Abstract][Full Text] [Related]
16. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women. Mouridsen HT Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085 [TBL] [Abstract][Full Text] [Related]
17. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. ; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061 [TBL] [Abstract][Full Text] [Related]
18. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148 [TBL] [Abstract][Full Text] [Related]
19. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ J Clin Oncol; 2005 Aug; 23(22):5178-87. PubMed ID: 15998905 [TBL] [Abstract][Full Text] [Related]